Y-mabs announces pipeline update

New york, dec. 14, 2022 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update for naxitamab and the company's sada technology programs will be presented at the company's r&d event, which will take place today at 9 a.m. eastern time.
YMAB Ratings Summary
YMAB Quant Ranking